Grants per year
Fingerprint
Dive into the research topics where Brendan Curti is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response
Curti, B. (PI) & Redmond, W. (CoPI)
08/2/21 → 07/31/27
Project: Research
-
Augmenting OX40 Immunotherapy in Men with Advanced Prostate Cancer
Curti, B. (PI)
01/1/10 → …
Project: Research
-
Ipilimumab plus a galectin-3 inhibitor for metastatic melanoma
Curti, B. (PI) & Redmond, W. (CoPI)
07/6/15 → 06/30/16
Project: Research
-
Clinical and Immunological Effects of SBRT and IL-2 in Metastatic Melanoma
Crittenden, M. (PI) & Curti, B. (CoPI)
04/1/13 → 03/31/16
Project: Research
-
-
Checkpoint Immunotherapy for Melanoma - Offering Hope for Cure.
Curti, B. D., Jan 2 2025, In: New England Journal of Medicine. 392, 1, p. 81-82 2 p.Research output: Contribution to journal › Editorial
3 Scopus citations -
Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial
Park, J. C., Curti, B., Butler, M., Wehrenberg-Klee, E., Elassal, J., Tighe, R., Battula, S., Iodice, G., Kaufman, H. L. & Kirkwood, J. M., Dec 2025, In: Nature Communications. 16, 1, 8567.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC): updated safety and efficacy from the phase 1 TRAVERSE multicenter study
Srour, S., Curti, B. & comments, S. F. L. O. A. I., Nov 1 2024Research output: Other contribution
-
A phase 1, open-label, dose escalation study on the safety and tolerability of ANK-101 in advanced solid tumors
Park, J. C., Curti, B. & comments, S. F. L. O. A. I., Jun 1 2024Research output: Other contribution
-
A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumab
Moser, J. C., Opyrchal, M., Rivera, I. R., Curti, B. D., Puzanov, I., Sosman, J. A., Bilen, M. A., Morris, K., Nirschl, C. J., Park, S., Bruno, M., Windt, P., Subramanian, K. K., Schönborn-Kellenberger, O., Chopra, S. & Isaacs, R., 2024, In: Journal of Clinical Oncology. 42, 16, 2623.Research output: Contribution to journal › Article › peer-review